Roche sees need for "real" biosimilars, assesses strategy for the sector
This article was originally published in Scrip
Roche continues to emphasise that biosimilars will never be quite the same as the innovator product, although the company appears to be evaluating its strategic options on how to position itself in the face of potential competition from biosimilars.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.